Turpie 1983.

Study characteristics
Methods	Randomisation: identical, sequentially numbered bottles from pharmacy Double blind Exclusions during trial: 4 (2 treatment, 2 control) Losses to follow‐up: none
Participants	Canada 53 participants 21 (40%) male Age range: 33–92 years No CT before entry Any stroke with leg paresis < 4 weeks since stroke onset (most < 2 weeks)
Interventions	Treatment: ticlopidine 250 mg orally 12 hourly Control: placebo Duration: 10–21 days
Outcomes	Death DVT (systematic I125 scan/plethysmography and venography) Pulmonary embolism (symptomatic) Intracranial haemorrhage (symptomatic) Extracranial haemorrhage
Funding source	No information available
Notes	Exclusions: unknown Follow‐up: 21 days
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Unable to assess risk of bias.
Allocation concealment (selection bias)	Unclear risk	Unable to assess risk of bias.
Blinding of participants and personnel (performance bias) all outcomes	Unclear risk	Unable to assess risk of bias.
Blinding of outcome assessment (detection bias) all outcomes	Unclear risk	Unable to assess risk of bias.
Incomplete outcome data (attrition bias) all outcomes	Unclear risk	Unable to assess risk of bias.
Selective reporting (reporting bias)	Unclear risk	Unable to assess risk of bias.
Other bias	Unclear risk	Unable to assess risk of bias.